Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Meyer, T.; Zhang, J.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Xu, F.; Eli, L. D.; Harding, J. J.; O'Reilly, E. M.; Lalani, A. S.; Bryce, R.; Gordan, J. D. |
| Abstract Title: | Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC) |
| Meeting Title: | 2021 Gastrointestinal Cancers Symposium (ASCO GI) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 15-17 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-01-20 |
| Language: | English |
| ACCESSION: | WOS:000636712800327 |
| DOI: | 10.1200/JCO.2021.39.3_suppl.310 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 310 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
